

Sector View

Hotels & Tourism

Top picks: ...and the winner is Melia.

	1 M	3 M	6 M	31/12/15
Travel&Leisure	-3.2%	-0.7%	-6.3%	-16.3%
DJ Stoxx 600	-1.1%	5.6%	1.5%	-7.1%

*Stoxx Sector Indices

Companies covered

Company	Recommendation	Price	Market Cap.
ACCORHOTELS	BUY	EUR42	
Last Price	EUR34.98	Market Cap.	EUR9,959m
InterContinental Hotels	SELL vs. NEUTRAL	2950p vs. 2650p	
Last Price	3098p	Market Cap.	GBP6,119m
MELIA	BUY	EUR15	
Last Price	EUR11.23	Market Cap.	EUR2,580m

LOOKING BACK ON Q3 2016

With c. 28% of the total number of rooms in France and despite a degree of resilience compared with the sector, **AccorHotels'** valuation was harshly impacted by the current turbulent environment in the country. In fact, **Accorhotels** only gained 2.3% in Q3 in absolute terms after losing 13.3% in H1 and lagging the DJ Stoxx by 2.9% (-3.8% in H1). On the other hand and benefitting from a better environment in their respective main geographies, **Melia** reported a strong outperformance of 17.6% in absolute terms (the stock was down 20.6% in H1) and 11.6% vs. the DJ Stoxx (-12% in H1) ahead of **IHG**, up 14.7% in absolute term and in euro (-8.5% in H1) and 8.7% vs. DJ Stoxx (+14.4% in H1).

In **dependence care**, share price volatility remained on **Korian** in Q3, up 0.8% in absolute terms (-13.6% in H1 o/w -23.1% in Q1 and +12.4% in Q2) and down 2.9% vs. DJ Stoxx. In Q3, **Orpea** was up 6.5% (+0.4% in H1) in absolute terms and 2.6% vs. the DJ Stoxx (+11.3% in H1).

WHAT WE SEE FOR Q4 2016


Q3 releases are set to be mixed be again between hoteliers.

AccorHotels results will again be affected by the group's exposure to France bearing in mind that RevPAR in July and August was respectively down 6% and 13.4%. Despite this trend, at the road show we organised early September in Paris, the group confirmed that FY guidance is still valid with an EBIT now in the low range of the EUR670/EUR720m (our current expectation is EUR695m and consensus at EUR685m). Nevertheless, September and October, the last two significant months of the year, need to be more favourable to valid this FY guidance!...

Meanwhile, **Melia Hotels** and **IHG** should deliver sustained numbers benefiting from positive RevPAR trends in Spain (51% of Melia offer in number of rooms) and in the Americas (64% of IHG offer mainly from NA).

In Spain, after RevPAR growth of 17.6% and 14% in July and August respectively, **Melia Hotels** confirmed that September looked pretty good in **Spain Resort** (33% of group offer) with occupancy in line with the August level, Q3 RevPAR growth in **Spain City** (18% of group offer) was in line with Q2 i.e. up 10% and RevPAR growth in the Americas (29%) will return to positive territory benefiting notably from better comps.

Regarding **IHG**, despite high comps, RevPAR growth continues in the US with July and August up 2.5% and 2.1%. Nevertheless, growth is slowing month after month with reported occupancy regularly in negative numbers (-0.4% in August after -1% in July). Moreover, with favourable financial conditions, room supply has increased while demand has decreased. Taking into account these numbers, STR from HNN estimates that US RevPAR should be up 3.2% in 2016e (compared with RevPAR up 6.3% in 2015) with no growth in occupancy and ADR up 3.2%. US RevPAR is expected to rise 2.8% in 2017e (occupancy down 0.3% with ADR up 3.1%).



US market trends

Demand Growth Slows. Supply Growth Increases To 1.4%.



Why Wall Street Is So Blue: Growth of RevPAR Growth Is Slowing



Confirming our FY 2016 forecasts based on RevPAR growth for the group of 2.3% after 2% in H1 o/w 2.5% in Q2 (2016e total revenue of USD1,773m down 1.6% vs. consensus USD1,743m with EBIT of USD685m and consensus of USD695m), **we move our recommendation to Sell vs. Neutral with a FV adjusted to 2,950p** using a DCF with WACC of 7.75% taking into account **1)** current market trends especially in the US, **2)** no more significant cash returns to shareholders due to disposals after the sale of InterContinental Hong Kong the last main fully-owned asset (the group returned US\$1.5bn in May

2016 bearing in mind that since 2003, the cash returned to shareholders including ordinary dividends amounted to US\$12,1bn with seven hotels fully owned today on a system size total number of 5,070). Note that at the end of H1 2016, net debt/EBITDA was at 2.3x vs. the group's guidance of 2-2.5x (our estimate is over 2x for the next three years) and **3**) valuation with, based on consensus estimates, EV/EBITDA 2016e at 13.3x and 12.5x 2017e which compares with historical median of 11.6x.

CONCLUSIONS AND TOP PICKS

Despite the strong outperformance in Q2, we are maintaining **Melia Hotels** as our top pick pending positive Q3 numbers mainly driven by Spain and despite the potential negative impacts of Brexit since British Citizens represented 12% of total room nights.

With sustained Q3 results, we remain confident on 2016e earnings in particular with EBITDA w/o capital gains of EUR274m compared with a consensus average of EUR269m (estimates from EUR266m and EUR274m).

Thereafter, as stated in our last note, there is room for improvement in operating results over three years (EBITDA w/o asset rotation 2015-2018 CAGR of c. 13%) primarily driven by Spanish city (EUR30m), Asia (EUR10m) and the Americas (EUR10m from Cuba).

Regarding **Spanish cities**, with 18% of the total group's number of rooms, the EBIT contribution is only 8%. In 2015, RevPAR was about 12% lower than in 2007, previous RevPAR highs. In 2016, RevPAR is likely to be not far off previous RevPAR highs but EBIT will again be lower by around EUR30m (i.e. representing 18% of 2015's consolidated EBIT of EUR164m) compared to 2007 with a still less favourable split between occupancy and daily rate.

AccorHotels' highlight: Short term positive news flow.

The group will hold a CMD on 5th October in Paris. Following the go-ahead given by the Board of Directors in mid-July for the project to turn HotelInvest into a subsidiary, **a new GAV will be given which should be higher than at the end of 2015**. Moreover, and as we understood during our recent road show in Paris with CFO and IRs, management should also detail what could be the use of the cash received i.e. EUR5bn based on 70% of HotelInvest sold.

In our view, we estimate that without specific needs (HotelServices being an asset light business), except new investment in discrepancy businesses, a significant sum (EUR3bn) could be returned to shareholders. In our view, the only reason for AccorHotels to retain the cash would be in anticipation of a mega consolidation in order to have the best assets to manage such a deal.

NEXT CATALYSTS

IHG: Commercial Strategy (London) on 29th September; Q3 US RevPAR on 21st October

AccorHotels: Capital Market day (Paris) on 5th October; Q3 Revenue on 18th October

Melia Hotels: Q3 results on 7th November

Orpea: H1 Full results on 28th September;

Korian: Q3 Revenue on 26th October

[Click here to download](#)



Analyst :

Bruno de La Rochebrochard

33(0) 1 56 68 75 88

bdelarochebrochard@bryangarnier.com

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.8%

NEUTRAL ratings 33.1%

SELL ratings 11%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			Geneva
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.